Literature DB >> 21460492

Emergence of daptomycin-resistant VRE: experience of a single institution.

Mini Kamboj1, Nina Cohen, Kathleen Gilhuley, N Esther Babady, Susan K Seo, Kent A Sepkowitz.   

Abstract

Recent surveillance from US hospitals shows that more than 99.5% of vancomycin-resistant enterococci (VRE) isolates remain susceptible to daptomycin. This report describes emergence of daptomycin-resistant VRE at a major cancer center. The percentage of patients with daptomycin-resistant VRE bacteremia increased from 3.4% in 2007 to 15.2% in 2009 ([Formula: see text]). Without susceptibility data, empiric daptomycin therapy for VRE infections should be used with caution.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21460492      PMCID： PMC3676937          DOI： 10.1086/659152

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  10 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

3.  Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.

Authors:  James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  De novo daptomycin nonsusceptibility in a clinical isolate.

Authors:  Emil P Lesho; Glenn W Wortmann; David Craft; Kimberly A Moran
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

5.  Mechanisms of resistance to daptomycin in Enterococcus faecium.

Authors:  Clemente I Montero; Frida Stock; Patrick R Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

6.  Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis.

Authors:  Carlos A DiazGranados; Shanta M Zimmer; Mitchel Klein; John A Jernigan
Journal:  Clin Infect Dis       Date:  2005-06-28       Impact factor: 9.079

7.  Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia.

Authors:  Jennifer K Long; Toni K Choueiri; Geraldine S Hall; Robin K Avery; Mikkael A Sekeres
Journal:  Mayo Clin Proc       Date:  2005-09       Impact factor: 7.616

Review 8.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

9.  Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin.

Authors:  M H Fraher; G D Corcoran; S Creagh; E Feeney
Journal:  J Hosp Infect       Date:  2007-02-20       Impact factor: 3.926

10.  Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

Authors:  Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2009-10       Impact factor: 2.803
  10 in total
  27 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

3.  Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Authors:  B J Werth; M E Steed; C E Ireland; T T Tran; P Nonejuie; B E Murray; W E Rose; G Sakoulas; J Pogliano; C A Arias; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

4.  False daptomycin-nonsusceptible MIC results by Microscan panel PC 29 relative to Etest results for Staphylococcus aureus and enterococci.

Authors:  Elizabeth L Palavecino; Jacqueline M Burnell
Journal:  J Clin Microbiol       Date:  2012-10-17       Impact factor: 5.948

Review 5.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

6.  Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure.

Authors:  Adam J DiPippo; Frank P Tverdek; Jeffrey J Tarrand; Jose M Munita; Truc T Tran; Cesar A Arias; Samuel A Shelburne; Samuel L Aitken
Journal:  J Infect       Date:  2016-11-11       Impact factor: 6.072

Review 7.  Resistance in Vancomycin-Resistant Enterococci.

Authors:  William R Miller; Barbara E Murray; Louis B Rice; Cesar A Arias
Journal:  Infect Dis Clin North Am       Date:  2020-12       Impact factor: 5.982

Review 8.  Antimicrobial resistance in nephrology.

Authors:  Tina Z Wang; Rosy Priya L Kodiyanplakkal; David P Calfee
Journal:  Nat Rev Nephrol       Date:  2019-08       Impact factor: 28.314

9.  The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Rosemary Soave; Alexandra C Racanelli; Tsiporah B Shore; Koen van Besien; Stephen G Jenkins; Thomas J Walsh
Journal:  Leuk Lymphoma       Date:  2014-03-24

10.  Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.

Authors:  Razieh Kebriaei; Seth A Rice; Kavindra V Singh; Kyle C Stamper; An Q Dinh; Rafael Rios; Lorena Diaz; Barbara E Murray; Jose M Munita; Truc T Tran; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.